The U.S. Food and Drug Administration (FDA) already declared that shortages of popular GLP-1 medications have ended, CNN reported. Those medications include semaglutide (Ozempic and Wegovy) and ...

The FDA has approved Starjemza (ustekinumab-hmny), a biosimilar to Stelara (ustekinumab), for the treatment of various chronic inflammatory diseases.

The Food and Drug Administration has designated Hadlima (adalimumab-bwwd) an interchangeable biosimilar to Humira (adalimumab).

Bimekizumab use for 4 years among patients with plaque psoriasis is associated with sustained efficacy outcomes and no new safety signals.

The disease burden of atopic dermatitis was high in pediatric patients, but factors affecting the burden differed between adolescents and children.

The Food and Drug Administration has approved Zoryve (roflumilast) topical foam, 0.3% for plaque psoriasis of the scalp and body.

Conversations in Dermatology: 2025 will focus on clinical challenges and recent advances that health care providers who manage chronic pruritic conditions should know.

Rilzabrutinib is a promising treatment option for patients with chronic spontaneous urticaria who are refractory to antihistamines.

A new COVID-19 variant, NB.1.8.1, has spread in the Mediterranean, Southeast Asia, and Western Pacific regions.

Patients with uveitis had a higher risk for psoriatic arthritis and psoriasis, whereas those with psoriatic arthritis had a higher risk for uveitis.

Numerous autoimmune diseases are associated with the development of age-related macular degeneration (AMD), according to ...

The FDA has announced its plan for systematically reviewing food additives already commercially available for the first time.